Five top-line data read-outs to watch for in Q2
This article was originally published in Scrip
Executive Summary
The first three months of 2014 did not disappoint when it came to interesting top-line data read-outs for novel products, with news of Roche/Genentech's Phase III crash for MetMab being the most-read story so far this year in Scrip by some margin.